Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension

(Children's National Health System) A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 inhibitors in pediatric patients with pulmonary hypertension published Feb. 24, 2017 in Pediatrics demonstrates that scientific evidence supports the use of this class of medications in infants, neonates and children with pulmonary hypertension.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news